Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Simulect®
( basiliximab )Immunology and DermatologyAvailable in -
Systane®
( polyethylene glycol 400, propylene glycol )OphthalmologyAvailable in -
Systane® Balance
( propylene glycol )OphthalmologyAvailable in -
Systane® Hydration
( polyethylene glycol 400, propylene glycol, hyaluronic acid )OphthalmologyAvailable in -
Systane® Ultra
( polyethylene glycol 400, propylene glycol )OphthalmologyAvailable in -
Tabrecta®
( capmatinib )Oncology -
Tafinlar®
( dabrafenib )Oncology -
Tasigna®
( nilotinib )Oncology